

# **Patient Group Direction**

# Supply of Hydrocortisone 1% cream or ointment by Community Pharmacists for the Management of Mild Skin Conditions Protocol number 504 Version 3

Date protocol prepared: March 2021

Date protocol due for review: March 2023

Expiry date: March 2024

This patient group direction must be signed by all health care professionals involved in its use. The NHS organisation should hold the original signed copy. The PGD must be easily accessible in the clinical setting.

Organisation	NHS Forth Valley

Job Title	Name	Signature	Date
Director of Nursing	Angela Wallace	Signed by Angela Wallace	19/4/21
Medical Director	Andrew Murray	Signed by Andrew Murray	20/4/21
Director of Pharmacy	Scott Mitchell	Signed by Scott Mitchell	21/4/21

This document authorises the supply of **Hydrocortisone 1% cream/ointment** by appropriate practitioners to patients who meet the criteria for inclusion under the terms of the document.

Practitioners seeking to supply **Hydrocortisone 1% cream/ointment** must ensure that they assess all clients to make sure they meet the criteria before supplying the product.

The purpose of this Patient Group Direction is to help patients by ensuring that they have ready access to a quality assured service which provides a timely, consistent and appropriate supply of **Hydrocortisone 1% cream/ointment** for the treatment of **mild skin conditions** patients.

Signatures of those developing the Patient Group Direction

Job Title	Name	Signature	Date
Doctor	David Herron	Signed by David Herron	1/4/21
Pharmacist	Kirstin Cassells	Signed by Kirstin Cassells	1/4/21
Nurse			
Microbiologist			
(if appropriate)			
Paediatrician (if appropriate)	David Watson	Signed by David Watson	16/4/21

Approval from Patient Group Directions Group

	Chair	Signed on behalf of group	Date
Patient Group	Scott Mitchell	Signed by Scott Mitchell	21/4/21
Directions Group		•	

# Lead Author responsible for updating change history: Kirstin Cassells

Change history

Version	Date	Summary of changes
3	25/1/21	Records/audit trail section updated with detail on retention of records
		for children
3	8/2/21	Title of PGD updated to include ointment
3	8/2/21	Name, form & strength of medicine section updated to include
		ointment

The following Patient Group Direction for Supply of Hydrocortisone 1% cream/ointment by Community Pharmacists for the Management of Mild Skin Conditions may be used from the following business/practice:

N	ame:
TI	ann.

Address:

YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

# **CLINICAL CONDITION**

Indication	Treatment of mild inflammatory skin conditions
Inclusion Criteria  Exclusion Criteria	Adults and children over the age of 2 presenting with:  O Insect bite reaction O Allergic contact dermatitis O Mild eczema O Infected eczema (signs suggestive of infection – weeping, rapidly worsening rash, fever) O Rash failing to respond to therapy O Hypersensitivity to any component of the product O Absence of valid consent O Application to face, anogenital region or broken skin O Skin lesions caused by untreated bacterial, fungal or viral skin infection eg cold sores, chicken pox, acne, athlete's foot, ringworm or impetigo. O Pregnancy and breastfeeding
Caution/ Need for further advice	If treatment fails, contact GP Practice
Action if Patient declines or is excluded	Refer patient to GP Practice / Out Of Hours for review

#### DRUG DETAILS

DIVOG DE I AILO		
Name, form & strength	Hydrocortisone 1% cream or ointment	
of medicine		
Legal Status	POM	
Route/ Method	Topical	
Dosage	One application	
Frequency	Apply sparingly twice daily	
Duration of treatment	Maximum 7 days	

Maximum or minimum treatment period	Maximum 7 days
Quantity to Supply/ administer	30g
Side Effects	Spreading and worsening of untreated infection, thinning of skin and pigmentation changes.  For a full list of side effects – refer to the marketing authorisation
	holder's Summary of Product Characteristics (SPC). A copy of the SPC must be available to the health professional administering medication under this Patient Group Direction. This can be accessed on <a href="https://www.medicines.org.uk">www.medicines.org.uk</a>
	All adverse reactions that are serious or result in harm should be reported to the MHRA through the Yellow Card Scheme <a href="https://yellowcard.mhra.gov.uk/">https://yellowcard.mhra.gov.uk/</a>
Advice to patient/carer	If symptoms have not improved after 7 days treatment, then patients should be advised to seek further medical advice.
	Advise patient of self-management strategies for managing skin conditions including using emollients frequently.
	Inform patient of possible side effects and their management and who to contact should they be troublesome.
	Advise patient of the importance of using Hydrocortisone cream/ointment twice daily for a maximum of 7 days.
	The Drug Manufacturer Patient Information Leaflet should be given.
	Patients should be informed who to contact should they experience an adverse drug reaction.
Follow up	Advise patient to seek medical advice should symptoms worsen or not improve

### STAFF CHARACTERISTICS

SIAII CHANACILIN	101100
Qualifications	Pharmacist currently registered with the General Pharmaceutical
	Council.
Specialist	
competencies or	Any pharmacist approved under local training
Qualifications	7.1 11 0
Continuing Training &	Up to date knowledge in therapeutic area
Education	

# **REFERRAL ARRANGEMENTS & AUDIT TRAIL**

	TAIL TO GROUNT INAIL
Referral arrangements	If symptoms have not improved after 7 days treatment, then
	patients should be advised to seek further medical advice.
Records/audit trail	A record of supply should be made on PMR which includes
	Name, strength, form and pack size of medicine supplied
	Dose and route of administration
	Date of supply and name of person making supply
	Date of supply and frame of person making supply
	The medicine must be labelling in accordance with requirements
	detailed in the current version of Medicines, Ethics and Practice.
	detailed in the editent version of Medicines, Edites and Fractice.
	The GP must be notified that a supply has taken place using the GP
	notification form. The patient's GP must be informed if the patient
	experiences an adverse drug reaction.
	A computer or manual record of all individuals receiving a supply
	under this PGD should also be kept for audit purposes.
	dilder tills PGD should also be kept for addit purposes.
	/ / / / / / / / / / / / / / / / / / / /
	Any adverse events/incidents should be reported to the PGD
	group in addition to any existing pharmacy processes
	For children retain records until the patient's 25th birthday or
	26th if young person was 17 at conclusion of treatment,
	or 3 years after death.
	For adults records of supply should be kept for 8 years.
Reference sources and	
comments	Electronic Medicines Compendium ( <u>www.medicines.org.uk</u> )
Comments	Current edition of the British National Formulary (BNF)

# PATIENT GROUP DIRECTION AUTHORISATION DOCUMENT

Supply of Hydrocortisone 1% cream or ointment by Community Pharmacists for the management of mild skin conditions working in Forth Valley Community **Pharmacies** 

protocol number 504 version 3
Individual Authorisation
This PGD does not remove inherent professional obligations or accountability
[ please print in capitals), confirm that I have read and understood the above Patient Group Direction. I confirm that I have the necessary professional registration, competence, and knowledge to apply the Patient Group Direction. I will ensure my competence is updated as necessary. I will have ready access to a copy of the Patient Group Direction in the clinical setting in which the supply of the medicine will take place and agree to provide this medicine only in accordance with this PGD.  I understand that it is the responsibility of the pharmacist to act in accordance with the Code of Ethics for Pharmacists and to keep an up to date record of training and competency. I understand it is also my responsibility to ensure that all consultations with patients occur within a private and confidential area of the pharmacy.  I have read and fully understand the Patient Group Direction for the supply of hydrocortisone cream/ ointment 1% and agree to provide this medicine only in accordance with this PGD in NHS Forth Valley Community Pharmacies.
Name of Pharmacist (in block capitals)
GPhC Number Employee  Locum  Relief Pharmacist
If you are a locum please provide a contact email address:
Normal NHS Forth Valley Pharmacy Location (Please state contractor code)
Signature

#### Note:

Date

A copy of this agreement must be signed by each pharmacy practitioner who wishes to be authorised to use the PGD for Supply of hydrocortisone 1 % cream or ointment by Community Pharmacists working in Forth Valley Pharmacies.

Please return this page either by mail to Community Pharmacy Development Team, NHS Forth Valley Royal Hospital, Stirling Road, Larbert, FK5 4WR OR by email to fv.communitypharmacysupport@nhs.scot attaching a scanned / photographed image. A copy should be retained in each pharmacy premises you provide the service in.

# PATIENT GROUP DIRECTION AUTHORISATION DOCUMENT Patient Group Direction for Supply of Hydrocortisone 1% cream or ointment by Community Pharmacists to Patients with mild skin conditions

Protocol No. 504 version 3

Name of Premises & Contra	actor Code
Address of Premises	

# PROFESSIONAL AGREEMENT

I have read and confirm that I have understood the above named patient group direction. **The people below have been authorised to use this protocol.** I confirm that I understand that it is my professional responsibility to ensure all those signed below are professionally registered and have undertaken all the mandatory training requirements to enable them to work under this PGD. A current version of the PGD is available in the above named premises.

Signature of Lead Pharmacist for the contractor code

Name (in block capitals)	Signature	Date

Name of Professional (IN BLOCK CAPITALS)	Registration Number	Signature	Date